IOVANCE BIOTHERAPEUTICS: Board & Executive Changes Announced
Ticker: IOVA · Form: 8-K · Filed: Jun 13, 2025 · CIK: 1425205
| Field | Detail |
|---|---|
| Company | Iovance Biotherapeutics, Inc. (IOVA) |
| Form Type | 8-K |
| Filed Date | Jun 13, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-of-directors, executive-compensation
Related Tickers: IOVA
TL;DR
IOVA board shakeup and exec comp changes filed. Watch for new direction.
AI Summary
On June 10, 2025, IOVANCE BIOTHERAPEUTICS, INC. announced changes to its board of directors and executive compensation. The company filed a Form 8-K detailing the departure of certain officers and the election of new directors, alongside updates to compensatory arrangements for its key executives.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, or financial outlook, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Board and executive changes can introduce uncertainty regarding future strategy and leadership stability.
Key Players & Entities
- IOVANCE BIOTHERAPEUTICS, INC. (company) — Registrant
- June 10, 2025 (date) — Date of earliest event reported
- Delaware (location) — State of Incorporation
- 001-36860 (other) — Commission File Number
- 75-3254381 (other) — I.R.S. Employer Identification No.
- Lion Biotechnologies, Inc. (company) — Former Company Name
- Genesis Biopharma, Inc (company) — Former Company Name
- FREIGHT MANAGEMENT CORP (company) — Former Company Name
FAQ
What specific roles have been affected by the departure of certain officers?
The filing indicates the departure of certain officers but does not specify the exact roles in the provided text.
Who are the newly elected directors?
The filing states that directors have been elected but does not name them in the provided text.
What are the key changes in the compensatory arrangements for certain officers?
The filing mentions updates to compensatory arrangements but does not detail the specific changes in the provided text.
What is the primary reason for this 8-K filing?
This 8-K filing is primarily to report the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.
When was the company formerly known as Lion Biotechnologies, Inc.?
The company's name changed from Lion Biotechnologies, Inc. on October 15, 2013.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 13, 2025 regarding IOVANCE BIOTHERAPEUTICS, INC. (IOVA).